PFS
KLRS

Prospera Financial Services’s Kalaris Therapeutics KLRS Stock Holding History

Prospera Financial Services’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-103
Closed -$9K – 1625
2022
Q2 		$9K Hold
103
– – ﹤0.01% 1374
2022
Q1 		$16K Buy
+103
New +$20.5K ﹤0.01% 1848

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prospera Financial Services's KLRS Position: Q3 2022 in Review

Prospera Financial Services sold out of Kalaris Therapeutics (KLRS) in Q3 2022, closing a stake of 103 shares — an estimated $9K sold.

Prospera Financial Services first reported a position in KLRS in Q1 2022 and held it in 2 quarters. The position peaked at $16K in Q1 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q3 2022.

  • Prospera Financial Services reported no remaining Kalaris Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Prospera Financial Services sold 103 Kalaris Therapeutics shares in Q3 2022, an estimated $9K.
  • Prospera Financial Services first reported a position in Kalaris Therapeutics in Q1 2022 and held it in 2 quarters.
  • Prospera Financial Services's Kalaris Therapeutics position peaked at $16K in Q1 2022.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2022.

Based on Prospera Financial Services's 13F filing for Q3 2022, filed 27 Oct 2022.